A DOUBLE-BLIND CLINICAL TRIAL OF VINPOCETINE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY OF VASCULAR AND DEGENERATIVE ORIGIN 

E. MANCONI, P. BINAGHI, F. PITZUS

Department of Internal Medicine, 
University of Cagliari, Cagliari, Italy
Curr Therap Res 1986; 40: 702-2

Abstract

We used vinpocetine, a synthetic ethyl ester of apovincamine, to treat 22 elderly patients with central nervous system degenerative disorders, in a double-blind clinical trial.  Patients received 10 mg vinpocetine TID for 30 days, then 5 mg TID for 60 days. Another 18 elderly patients were given matching placebo tablets for the 90-day trial.  Vinpocetine-treated patients scored consistently better in all evaluations of the effectiveness of treatment, including measurements on the Clinical Global Impreasions (CGI) and Sandoz Clinical Assessment-Geriatric (SCAG) scales, and the Minl-Mental Status Questionnaire.  According to CGI assessments, severity of illness decreased in 73% of the patients in the vinpocetine group at day 30 and 77% at day 90, and improvement was seen in 77% and 87% of the patients at days 30 and 90, respectively. Patients also showed statistically significant improvement for all SCAG items but one, at days 30 and 90. The physician rated the improvement in 59% of the vinpocetine-treated patients as "good" to "excellent". No serious side effects were related to the treatment drug.

Home | Order
www.AlzheimersTreatments.com

   1.   vinpocetine  treatment in acute stroke
   2.   vinpocetine  redistributes cerebral blood flow in post-stroke patients
   3.   vinpocetine  cerebral effects on stroke patients
   4.   vinpocetine  mechanism of action
   5.   vinpocetine  increases cerebral blood flow in stroke patients 
   6.   vinpocetine  in the treatment of cerebrovascular disorders
   7.   vinpocetine  as a free radical scavenger
   8.   vinpocetine  safety
   9.   vinpocetine  treatment for vascular senile cerebral dysfunction
 10.   vinpocetine  safety and efficacy
 11.   vinpocetine  improved visual acuity in 88% of subjects
 12.   vinpocetine  is indicated in ischemic disorders of cerebral circulation
 13.   vinpocetine  might increase adaptation to hypoxia
 14.   vinpocetine  use in dementia
 15.   vinpocetine  significantly reduced neuronal cell loss
 16.   vinpocetine  caused significant and quick improvement in vascular diseases
 17.   vinpocetine  increases cerebral blood flow
 18.   vinpocetine  enhances the glycolytic and oxidative glucose breakdown in CNS
 19.   vinpocetine  increases regional cerebral blood flow
 20.   vinpocetine  enhances oxygen release in vascular dementia 
 21.   vinpocetine  has a protective effect against cerebral ischemia
 22.   vinpocetine  improvemed red blood cell deformability in stroke patients
 23.   vinpocetine  study of patients with cerebrovascular disorders
 24.   vinpocetine  improved 87% of patients with central nervous system disorders
 25.   vinpocetine  significantly improved memory
 26.   vinpocetine  dose of 5mg caused increased cerebral blood flow
 27.   vinpocetine  might prove effective in augmenting cerebral blood flow
 28.   vinpocetine  was associated with improvement in short-term memory
 29.   vinpocetine  significant improvement in short-term memory test

Home | Order